Targeting glutamine metabolism in PIK3CA mutant colorectal cancers

被引：13
|
作者：
Feng, Xiujing
Hao, Yujun
Wang, Zhenghe [1 ]
机构：
[1] Case Western Reserve Univ, Dept Genet & Genome Sci, Cleveland, OH 44106 USA
来源：
GENES & DISEASES | 2016年 / 3卷 / 04期
基金：
美国国家卫生研究院;
关键词：
D O I：
10.1016/j.gendis.2016.09.001
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
We recently reported that PIK3CA mutant colorectal cancers (CRCs) are addicted to glutamine through up-regulation of glutamate pyruvate transaminase 2 (GPT2). A GPT2 inhibitor suppresses in vivo growth of PIK3CA mutant, but not wild-type, CRCs. This study indicates that targeting glutamine may be an effective approach to treat CRCs with PIK3CA mutations. Copyright (C) 2016, Chongqing Medical University. Production and hosting by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
引用
收藏
页码：241 / 243
页数：3
相关论文
共 50 条
  • [21] PIK3CA: a Target or a Marker in Breast Cancers
    Dieci M.V.
    Guarneri V.
    [J]. Current Breast Cancer Reports, 2015, 7 (3) : 161 - 169
  • [22] Mutation of the PIK3CA oncogene in human cancers
    B Karakas
    K E Bachman
    B H Park
    [J]. British Journal of Cancer, 2006, 94 : 455 - 459
  • [23] Oncogenic mutations of PIK3CA in human cancers
    Samuels, Y
    Velculescu, VE
    [J]. CELL CYCLE, 2004, 3 (10) : 1221 - 1224
  • [24] Clinicopathological analysis of colorectal cancers with PIK3CA mutations in Middle Eastern population
    Abubaker, Jehad
    Bavi, Prashant
    Al-Harbi, Sayer
    Ibrahim, Muna
    Ai-Sanea, Nasser
    Jabbar, Alaa Abdul
    Ashari, Luai
    Alhomoud, Samar
    Al-Dayel, Fouad
    Uddin, Shahab
    Al-Kuraya, Khawla
    [J]. MOLECULAR CANCER THERAPEUTICS, 2007, 6 (12) : 3486S - 3487S
  • [25] Clinicopathological analysis of colorectal cancers with PIK3CA mutations in Middle Eastern population
    Abubaker, J.
    Bavi, P.
    Al-Harbi, S.
    Ibrahim, M.
    Siraj, A. K.
    Al-Sanea, N.
    Abduljabbar, A.
    Ashari, L. H.
    Alhomoud, S.
    Al-Dayel, F.
    Uddin, S.
    Al-Kuraya, K. S.
    [J]. ONCOGENE, 2008, 27 (25) : 3539 - 3545
  • [26] NSAIDs Increase Survival for Mutant PIK3CA
    不详
    [J]. JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2019, 139 (05) : 980 - 980
  • [27] Mutant PIK3CA in AML and sensitivity to therapy
    Libra, Massimo
    Ligresti, Giovanni
    Pezzino, Franca Maria
    Basecke, Jorg
    Steelman, Linda S.
    Abrams, Stephen L.
    McCubrey, James A.
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 2012, 30 : S56 - S56
  • [28] Dual PI3K/mTOR inhibition in PIK3CA mutant pancreatic cancers
    Payne, Susan
    Depke, Mitchell
    Yueh, Alex
    Sharick, Joseph T.
    Favreau, Peter F.
    Pasch, Cheri A.
    Clipson, Linda
    Matkowskyj, Kristina A.
    Skala, Melissa
    Deming, Dustin A.
    [J]. CANCER RESEARCH, 2018, 78 (13)
  • [29] MTORC1/2 Inhibition as a Therapeutic Strategy for PIK3CA Mutant Cancers
    Fricke, Stephanie L.
    Payne, Susan N.
    Favreau, Peter F.
    Kratz, Jeremy D.
    Pasch, Cheri A.
    Foley, Tyler M.
    Yueh, Alexander E.
    Van De Hey, Dana R.
    Depke, Mitchell G.
    Korkos, Demetra P.
    Sha, Gioia Chengcheng
    DeStefanis, Rebecca A.
    Clipson, Linda
    Burkard, Mark E.
    Lemmon, Kayla K.
    Parsons, Benjamin M.
    Kenny, Paraic A.
    Matkowskyj, Kristina A.
    Newton, Michael A.
    Skala, Melissa C.
    Deming, Dustin A.
    [J]. MOLECULAR CANCER THERAPEUTICS, 2019, 18 (02) : 346 - 355
  • [30] MicroRNA-375 inhibits colorectal cancer growth by targeting PIK3CA
    Wang, Yihui
    Tang, Qingchao
    Li, Mingqi
    Jiang, Shixiong
    Wang, Xishan
    [J]. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2014, 444 (02) : 199 - 204
12345